EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes

Wei Zhang, Wen Yan, Mengyun Chen, Robert Peter Gale, Junren Chen

Acta Haematologica · 06.07.2026 · 1-10

DOI: 10.1159/000553384 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 06.07.2026. Verfasst von Wei Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Die Arbeit nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Improvement in progression-free survival (PFS) is increasingly used by health authorities for cancer drug approvals.

Method

We analyzed 106 randomized controlled trials (RCTs) with positive PFS outcomes published in JAMA Oncology, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology during 2020–2023. RCTs were categorized as “targeted” (n = 83) or “conventional” (n = 23) by their interrogated treatment variables. Two measures of PFS effect sizes were analyzed: hazard ratio (HR) and PFS increment.

Results

Among the RCTs of targeted therapies, the 25th-percentile value (Q1) of HR increased significantly (slope = 0.05 per year; p = 0.02) during the study period whilst Q1 of PFS increment decreased significantly (slope = −9.1 percentage points per year; p = 0.03). Similar trends were not observed among the RCTs of conventional therapies.

Conclusions

Our analyses suggest a potential bias in accepting RCTs of targeted therapies despite decreased PFS effect sizes.

Schlagwörter

Stichwörter der Autor:innen

CancersConventional therapiesProgression-free survivalRandomized controlled trialsTargeted therapies

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
  • Tianjin Institutes of Health Science, Tianjin, China.
  • Centre for Haematology, Department of Immunology and Inflammation, Imperial College of Science, Technology and Medicine, London, UK.
  • Tianjin Institutes of Health Science, Tianjin, China, chenjunren@ihcams.ac.cn.

Zitieren

APA

Zhang, W., Yan, W., Chen, M., Gale, R. P., & Chen, J. (2026). Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes. Acta Haematologica, 1-10. https://doi.org/10.1159/000553384

Vancouver

Zhang W, Yan W, Chen M, Gale RP, Chen J. Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes. Acta Haematologica. 2026:1-10. doi:10.1159/000553384

BibTeX
@article{Zhang2026,
  author = {Zhang, Wei and Yan, Wen and Chen, Mengyun and Gale, Robert Peter and Chen, Junren},
  title = {Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes},
  journal = {Acta Haematologica},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000553384}
}
Kostenlos starten →